Preoperative C-reactive protein/albumin ratio and mortality of off-pump coronary artery bypass graft
View abstract on PubMed
Summary
This summary is machine-generated.The C-reactive protein (CRP)-to-albumin ratio (CAR) can predict mortality in patients undergoing off-pump coronary artery bypass grafting (OPCAB). A high preoperative CAR indicates a significantly increased risk of 1-year mortality after OPCAB surgery.
Area Of Science
- Cardiology
- Surgical Outcomes
- Biomarkers
Background
- Off-pump coronary artery bypass grafting (OPCAB) is a common cardiac surgical procedure.
- Predicting patient mortality after OPCAB is crucial for clinical decision-making.
- Inflammatory markers are increasingly recognized for their prognostic value in surgical patients.
Purpose Of The Study
- To investigate the prognostic value of the preoperative C-reactive protein (CRP)-to-albumin ratio (CAR) for predicting 1-year mortality in patients undergoing OPCAB.
- To compare the predictive performance of CAR against other inflammatory markers.
Main Methods
- Retrospective analysis of 2,082 adult patients who underwent OPCAB between January 2010 and August 2016.
- Preoperative inflammatory markers including CAR, CRP, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio were recorded.
- Receiver operating characteristic (ROC) curves were used to determine optimal thresholds and compare marker predictive values. Patients were stratified into low and high CAR groups based on the optimal cut-off value.
Main Results
- During 1-year follow-up, 25 patients (1.2%) died post-OPCAB.
- CAR demonstrated a significant area under the curve (0.767) for predicting 1-year mortality, outperforming other inflammatory markers.
- A high preoperative CAR (cut-off 1.326) was significantly associated with increased 1-year mortality risk (Hazard ratio, 5.01; p < 0.001) after inverse probability weighting adjustment.
Conclusions
- Preoperative CAR is a valuable predictor of 1-year mortality in patients undergoing OPCAB.
- CAR may offer superior predictive power for mortality compared to other commonly used inflammatory markers in this patient population.
- Further prospective studies are warranted to validate these findings.

